BioLife Solutions Signs Supply Agreement With Hepatotech Inc.

[Guest guest]

BioLife Solutions Signs Supply Agreement With Hepatotech Inc.

BINGHAMTON, N.Y., Feb. 2 /PRNewswire-FirstCall/ -- BioLife Solutions

Inc.

(OTC Bulletin Board: BLFS) announced today that it has signed a multi-year

supply agreement with Pittsboro, NC-based Hepatotech Inc., a privately-held

manufacturer and distributor of hepatocytes (liver cells). Under the terms

of

the agreement, BioLife will sell Hepatotech its off-the-shelf

Hypothermosol®

and Cryostor preservation solutions to support Hepatotech's cell harvest

and shipment services. The agreement with the collaborating entities of

Hepatotech further expands the sales opportunities for BioLife's technology.

BioLife President and CEO G. Baust, Ph.D., said, " We look forward

to

working with Hepatotech to expand the distribution of our product offerings

to

their customers. This agreement represents a key milestone in the

implementation of our Company's strategy to expand our customer base via

such

sole source agreements to position BioLife to derive growing revenue streams

from a broader base of customers. "

BioLife's HypoThermosol family of products includes solutions optimized

for the " chill " storage of human cells and tissues. Its recently developed

CryoStor product line of cryopreservation media provides a superior approach

to the low temperature preservation of many biological systems.

About BioLife Solutions, Inc.

BioLife Solutions has pioneered the next generation of preservation

solutions designed to maintain the viability and health of cellular matter

and

tissues during freezing, transportation and storage. Based on the Company's

proprietary bio-packaging technology and a patented under-standing of the

mechanism of cellular damage and death, these products enable the

biotechnology and medical community to address a growing problem that exists

today. The expanding practice of cell and gene therapy has created a need

for

products that ensure the biological viability of mammalian cell and tissue

material during transportation and storage. The HypoThermosol® and

CryoStor products that the Company is selling today are a significant

step

forward in meeting these needs.

This news release contains forward-looking statements as that term is

defined in the Private Securities Litigation Reform Act of 1995. These

forward-looking statements include any statements that relate to the intent,

belief, plans or expectations of the Company or its management, or that are

not a statement of historical fact. Any forward-looking statements in this

news release are based on current expectations and beliefs and are subject

to

numerous risks and uncertainties that could cause actual results to differ

materially. Some of the specific factors that could cause BioLife Solutions'

actual results to differ materially are discussed in the Company's recent

filings with the Securities and Exchange Commission. BioLife Solutions

disclaims any obligation to update any forward-looking statements as a

result

of developments occurring after the date of this press release.

For further information please contact: investors, Jill Bertotti,

jill@..., or media, Len Hall, len@..., both of &

Caron Inc, +1-949-474-4300, for BioLife Solutions Inc.

SOURCE BioLife Solutions Inc.

[Guest guest]

BioLife Solutions Signs Supply Agreement With Hepatotech Inc.

BINGHAMTON, N.Y., Feb. 2 /PRNewswire-FirstCall/ -- BioLife Solutions

Inc.

(OTC Bulletin Board: BLFS) announced today that it has signed a multi-year

supply agreement with Pittsboro, NC-based Hepatotech Inc., a privately-held

manufacturer and distributor of hepatocytes (liver cells). Under the terms

of

the agreement, BioLife will sell Hepatotech its off-the-shelf

Hypothermosol®

and Cryostor preservation solutions to support Hepatotech's cell harvest

and shipment services. The agreement with the collaborating entities of

Hepatotech further expands the sales opportunities for BioLife's technology.

BioLife President and CEO G. Baust, Ph.D., said, " We look forward

to

working with Hepatotech to expand the distribution of our product offerings

to

their customers. This agreement represents a key milestone in the

implementation of our Company's strategy to expand our customer base via

such

sole source agreements to position BioLife to derive growing revenue streams

from a broader base of customers. "

BioLife's HypoThermosol family of products includes solutions optimized

for the " chill " storage of human cells and tissues. Its recently developed

CryoStor product line of cryopreservation media provides a superior approach

to the low temperature preservation of many biological systems.

About BioLife Solutions, Inc.

BioLife Solutions has pioneered the next generation of preservation

solutions designed to maintain the viability and health of cellular matter

and

tissues during freezing, transportation and storage. Based on the Company's

proprietary bio-packaging technology and a patented under-standing of the

mechanism of cellular damage and death, these products enable the

biotechnology and medical community to address a growing problem that exists

today. The expanding practice of cell and gene therapy has created a need

for

products that ensure the biological viability of mammalian cell and tissue

material during transportation and storage. The HypoThermosol® and

CryoStor products that the Company is selling today are a significant

step

forward in meeting these needs.

This news release contains forward-looking statements as that term is

defined in the Private Securities Litigation Reform Act of 1995. These

forward-looking statements include any statements that relate to the intent,

belief, plans or expectations of the Company or its management, or that are

not a statement of historical fact. Any forward-looking statements in this

news release are based on current expectations and beliefs and are subject

to

numerous risks and uncertainties that could cause actual results to differ

materially. Some of the specific factors that could cause BioLife Solutions'

actual results to differ materially are discussed in the Company's recent

filings with the Securities and Exchange Commission. BioLife Solutions

disclaims any obligation to update any forward-looking statements as a

result

of developments occurring after the date of this press release.

For further information please contact: investors, Jill Bertotti,

jill@..., or media, Len Hall, len@..., both of &

Caron Inc, +1-949-474-4300, for BioLife Solutions Inc.

SOURCE BioLife Solutions Inc.

[Guest guest]

BioLife Solutions Signs Supply Agreement With Hepatotech Inc.

BINGHAMTON, N.Y., Feb. 2 /PRNewswire-FirstCall/ -- BioLife Solutions

Inc.

(OTC Bulletin Board: BLFS) announced today that it has signed a multi-year

supply agreement with Pittsboro, NC-based Hepatotech Inc., a privately-held

manufacturer and distributor of hepatocytes (liver cells). Under the terms

of

the agreement, BioLife will sell Hepatotech its off-the-shelf

Hypothermosol®

and Cryostor preservation solutions to support Hepatotech's cell harvest

and shipment services. The agreement with the collaborating entities of

Hepatotech further expands the sales opportunities for BioLife's technology.

BioLife President and CEO G. Baust, Ph.D., said, " We look forward

to

working with Hepatotech to expand the distribution of our product offerings

to

their customers. This agreement represents a key milestone in the

implementation of our Company's strategy to expand our customer base via

such

sole source agreements to position BioLife to derive growing revenue streams

from a broader base of customers. "

BioLife's HypoThermosol family of products includes solutions optimized

for the " chill " storage of human cells and tissues. Its recently developed

CryoStor product line of cryopreservation media provides a superior approach

to the low temperature preservation of many biological systems.

About BioLife Solutions, Inc.

BioLife Solutions has pioneered the next generation of preservation

solutions designed to maintain the viability and health of cellular matter

and

tissues during freezing, transportation and storage. Based on the Company's

proprietary bio-packaging technology and a patented under-standing of the

mechanism of cellular damage and death, these products enable the

biotechnology and medical community to address a growing problem that exists

today. The expanding practice of cell and gene therapy has created a need

for

products that ensure the biological viability of mammalian cell and tissue

material during transportation and storage. The HypoThermosol® and

CryoStor products that the Company is selling today are a significant

step

forward in meeting these needs.

This news release contains forward-looking statements as that term is

defined in the Private Securities Litigation Reform Act of 1995. These

forward-looking statements include any statements that relate to the intent,

belief, plans or expectations of the Company or its management, or that are

not a statement of historical fact. Any forward-looking statements in this

news release are based on current expectations and beliefs and are subject

to

numerous risks and uncertainties that could cause actual results to differ

materially. Some of the specific factors that could cause BioLife Solutions'

actual results to differ materially are discussed in the Company's recent

filings with the Securities and Exchange Commission. BioLife Solutions

disclaims any obligation to update any forward-looking statements as a

result

of developments occurring after the date of this press release.

For further information please contact: investors, Jill Bertotti,

jill@..., or media, Len Hall, len@..., both of &

Caron Inc, +1-949-474-4300, for BioLife Solutions Inc.

SOURCE BioLife Solutions Inc.

[Guest guest]

BioLife Solutions Signs Supply Agreement With Hepatotech Inc.

BINGHAMTON, N.Y., Feb. 2 /PRNewswire-FirstCall/ -- BioLife Solutions

Inc.

(OTC Bulletin Board: BLFS) announced today that it has signed a multi-year

supply agreement with Pittsboro, NC-based Hepatotech Inc., a privately-held

manufacturer and distributor of hepatocytes (liver cells). Under the terms

of

the agreement, BioLife will sell Hepatotech its off-the-shelf

Hypothermosol®

and Cryostor preservation solutions to support Hepatotech's cell harvest

and shipment services. The agreement with the collaborating entities of

Hepatotech further expands the sales opportunities for BioLife's technology.

BioLife President and CEO G. Baust, Ph.D., said, " We look forward

to

working with Hepatotech to expand the distribution of our product offerings

to

their customers. This agreement represents a key milestone in the

implementation of our Company's strategy to expand our customer base via

such

sole source agreements to position BioLife to derive growing revenue streams

from a broader base of customers. "

BioLife's HypoThermosol family of products includes solutions optimized

for the " chill " storage of human cells and tissues. Its recently developed

CryoStor product line of cryopreservation media provides a superior approach

to the low temperature preservation of many biological systems.

About BioLife Solutions, Inc.

BioLife Solutions has pioneered the next generation of preservation

solutions designed to maintain the viability and health of cellular matter

and

tissues during freezing, transportation and storage. Based on the Company's

proprietary bio-packaging technology and a patented under-standing of the

mechanism of cellular damage and death, these products enable the

biotechnology and medical community to address a growing problem that exists

today. The expanding practice of cell and gene therapy has created a need

for

products that ensure the biological viability of mammalian cell and tissue

material during transportation and storage. The HypoThermosol® and

CryoStor products that the Company is selling today are a significant

step

forward in meeting these needs.

This news release contains forward-looking statements as that term is

defined in the Private Securities Litigation Reform Act of 1995. These

forward-looking statements include any statements that relate to the intent,

belief, plans or expectations of the Company or its management, or that are

not a statement of historical fact. Any forward-looking statements in this

news release are based on current expectations and beliefs and are subject

to

numerous risks and uncertainties that could cause actual results to differ

materially. Some of the specific factors that could cause BioLife Solutions'

actual results to differ materially are discussed in the Company's recent

filings with the Securities and Exchange Commission. BioLife Solutions

disclaims any obligation to update any forward-looking statements as a

result

of developments occurring after the date of this press release.

For further information please contact: investors, Jill Bertotti,

jill@..., or media, Len Hall, len@..., both of &

Caron Inc, +1-949-474-4300, for BioLife Solutions Inc.

SOURCE BioLife Solutions Inc.